Anti-Human CD340/ERBB2/HER2 & CD3E Bispecific Reference Antibody (Ertumaxomab, RUO)

Description: Ertumaxomab (BS10292) is a research-grade recombinant antibody targeting CD340. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.39mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: p185erbB2,HER2,NGL,Tyrosinekinase-typecellsurfacereceptorHER2,NEU,MLN19,Proto-oncogeneNeu,MLN19,ERBB2,Proto-oncogenec-ErbB-2,CD340,Receptortyrosine-proteinkinaseerbB-2,Metastaticlymphnodegene19protein,T3E,T-cellsurfaceantigenT3/Leu-4epsilonchain,CD3e,CD3E,T-cellsurfaceglycoproteinCD3epsilonchain
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,MusmusG2akappa,anti-ERBB2(250A/TP-A-02)/Ratsp.G2blambda,anti-CD3E(26/II/6-1.2),TPBs03,CAS:509077-99-0
Note: For research use only. Not suitable for clinical or therapeutic use.